Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Tables
Technology
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF
Net Letter
87 (
3
); 455-455
doi:
10.25259/IJDVL_125_20
pmid:
33871213
CROSSMARK LOGO Buy Reprints
PDF

Linezolid: A novel treatment option for the treatment of a non-responsive case of actinomycotic mycetoma

Department of Dermatology and Venereology All India Institute of Medical Sciences, New Delhi, India
Department of Pathology, All India Institute of Medical Sciences, New Delhi, India
Corresponding author: Dr. Neetu Bhari, Department of Dermatology and Venereology, All India Institute of Medical Sciences, Room No. 4070, 4th Floor Teaching Block, Ansari Nagar, New Delhi - 110 029, India. drntbhari@gmail.com
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Patra S, Senthilnathan G, Ramam M, Arava S, Bhari N. Linezolid: A novel treatment option for treatment non-responsive case of actinomycotic mycetoma. Indian J Dermatol Venereol Leprol 2021;87:455.

Sir,

Linezolid, an oxazolidinone antibiotic, is commonly used in the management of skin and soft tissue infections caused by Gram-positive bacteria, primarily, methicillin-resistant Staphylococcus aureus.1 Recent studies have shown its effectiveness against other species like Mycobacterium tuberculosis,2 non-tuberculous mycobacteria,3 Nocardia sp,4 Actinomadura madurae5, etc., which have broadened the scope of its use. Here, we report a case of actinomycotic mycetoma, non-responsive to the conventional treatment regimen, but showing complete improvement with linezolid monotherapy.

A 14-year-old Indian girl presented with an erythematous indurated plaque over the dorsal aspect of the left foot since 5 years. There was no preceding history of trauma and she did not have any systemic symptom. The plaque was 10 cm x 8.5 cm in size, extending from the ankle up to the dorsal surface of the toes and on the plantar aspect, up to the instep. There were multiple tiny sinuses over the surface of the plaque, along with proliferating granulation tissue [Figure 1]. Grains were not visible on examination. She responded poorly to short courses of oral antibiotics like amoxicillin and azithromycin as well as azole antifungals previously, and the lesion continued to grow in size. A clinical diagnosis of mycetoma was considered. Potassium hydroxide and gram stain smear prepared from the pus did not reveal any organism. Histopathology from the sinus showed grains with a dense mixed inflammatory infiltrate and eosinophilic material deposited around it. On higher magnification, grains were observed to have a variegated pattern with dark basophilic periphery and pale, less dense center, surrounded by eosinophilic material (Splendore Hoeppli phenomenon), characteristic of actinomycotic grain [Figure 2]. The culture from pus and skin biopsy did not grow any organism. Pan fungal polymerase chain reaction was negative. Magnetic resonance imaging of the foot showed heterogeneously enhanced mass on the dorsolateral aspect of the feet with no bone destruction. She was started on a regimen of injection amikacin 15 mg/kg IV daily and tab cotrimoxazole DS 2 tab twice daily. We chose amikacin in place of gentamycin in view of the better side effect profile and preferable once-daily dosing.6 After 1 month of the above regimen; the lesion did not show any significant improvement. According to the regimen in maintenance phase, injection amikacin was stopped and doxycycline 100 mg twice daily was added to cotrimoxazole. In the next 2 months, the lesion became more inflammatory and further progressed in size [Figure 3].

Cotrimoxazole and doxycycline were stopped in view of the lack of response and the patient was started on tablet linezolid 600 mg twice daily. The lesion started to respond within 2 weeks and a complete resolution was seen after 2 months of this therapy [Figure 4]. Complete blood count and liver function tests monitored at monthly intervals were found to be normal. The treatment was continued until 3 months following complete resolution.

Figure 1:: Erythematous indurated plaque with multiple sinuses and granulation tissue over the dorsum of left foot
Figure 2:: Dense infiltrate of neutrophils, lymphocytes, histocytes with purple colored actinomycotic grain with eosinophilic material around it (H and E, ×200). Grain was composed of thin filaments (inset: H and E, ×400)
Figure 3:: Increase in the size of the lesion after receiving three months of treatment in the initial regimen
Figure 4:: Complete resolution of the plaque with two months of treatment with linezolid

Mycetoma usually presents with swelling, induration and discharging sinuses over the extremities. Actinomycotic mycetoma is caused by filamentous bacteria like Nocardia brasiliensis, Actinomadura madurae, Actinomadura pelletieri, Streptomyces somaliensis, etc., while eumycotic mycetoma is caused by fungi like Madurella mycetomatis, Trematosphaeria grisea, Falciformispora senegalensis, Falciformispora tompkinsii, etc., Clinical features of these two subtypes are overlapping; thus, histopathological characteristics of grains are the mainstay of diagnosis in most of the cases.7 Special stains like Gram stain, Ziehl– Neelsen staining and potassium hydroxide mount of the grains as well as bacterial and fungal cultures also aid in diagnosis. Various injectable and oral antibiotics have been found to be useful in the management of actinomycotic mycetoma. Culture is negative in majority of the cases, so information regarding antibiotic sensitivity is usually not available and the treatment is given empirically.8 Welsh regimen (consisting of co-trimoxazole with amikacin for 3 weeks, followed by only co-trimoxazole for 2 weeks (constituting 1 pulse) for one to four such cycles9 and modified Ramam’s two-step regimen (“intensive phase” of co-trimoxazole and gentamicin for 4 weeks followed by a “maintenance phase” of co-trimoxazole and doxycycline)10,11 are the commonly used therapeutic regimens. Other modifications of the original Welsh regimen include adding rifampicin, dapsone, doxycycline and streptomycin in different combinations, or increasing the number of cycles, particularly in cases of bony involvement.8 In highly refractory cases, agents such as netilmicin can replace amikacin or an alternative treatment regimen like imipenem alone or with amikacin or amoxicillin–clavulanic acid have been used. Most have shown a cure rate of almost 90% with a treatment non-responsiveness in around 10% of cases.8 Therefore, it is important to have alternative drugs in the management of actinomycetoma. Linezolid has been found to have significant in vitro activity against Actinomadurae spp. and Nocardia spp.4,5 Considering these two species being the commonest causative agents of actinomycotic mycetoma, we considered linezolid as a treatment option, more so, in the setting of a lack of response to the conventional treatment regimen. Till date, though linezolid has been used successfully in the treatment of disseminated systemic Nocardia spp infections in a few occasions, we could not find any clinical study that has used it in the management of actinomycotic mycetoma.12 Considering the good response in our case, linezolid maybe considered as an alternative agent in the treatment of actinomycotic mycetoma.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

  1. , , , , . Linezolid: A promising option in the treatment of Gram positives. J Antimicrob Chemother. 2017;72:354-64.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , . Linezolid in the treatment of MDR TB: A retrospective clinical study. Int J Tuberc Lung Dis. 2012;16:358-63.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , . Activities of Linezolid against nontuberculous mycobacteria. New Microbiol. 2007;30:411-4.
    [Google Scholar]
  4. , , , , , . In vitro activities of linezolid against multiple Nocardia species. Antimicrob Agents Chemother. 2001;45:1295-7.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , , , , . In vitro activities of new quinolones and oxazolidinones against Actinomadura madurae. Antimicrob Agents Chemother. 2004;48:1037-9.
    [CrossRef] [PubMed] [Google Scholar]
  6. . A prospective comparative study of gentamicin and amikacin induced nephrotoxicity in patients with normal baseline renal function. Fundam Clin Pharmacol. 2009;23:515-20.
    [CrossRef] [PubMed] [Google Scholar]
  7. , , , , , . Mycetoma: A unique neglected tropical disease. Lancet Infect Dis. 2016;16:100-12.
    [CrossRef] [Google Scholar]
  8. , , . Drug therapy for Mycetoma. Cochrane Database Syst Rev. 2018;2018:CD013082.
    [CrossRef] [Google Scholar]
  9. , , , . Actinomycetoma and advances in its treatment. Clin Dermatol. 2012;30:372-81.
    [CrossRef] [PubMed] [Google Scholar]
  10. , , , , , , et al. A two step schedule for the treatment of actinomycotic mycetomas. Acta Derm Venereol. 2000;80:378-80.
    [CrossRef] [PubMed] [Google Scholar]
  11. , , , , , , et al. A modified two step treatment for actinomycetoma. Indian J Dermatol Venereol Leprol. 2007;73:235-9.
    [CrossRef] [PubMed] [Google Scholar]
  12. , , . Linezolid for the treatment of Nocardia spp. infections. Ann Pharmacother. 2007;41:1694-9.
    [CrossRef] [PubMed] [Google Scholar]

Fulltext Views
1169

PDF downloads
288
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections